CanSino Biologics announced that The Lancet published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia. The publication of the analysis showed that a single dose of Convidecia is efficacious and safe with an efficacy of 96.0% in preventing severe Covid-19 disease and an overall efficacy of 63.7% 14 days post-vaccination for healthy adults aged 18 and above, without any reported vaccine-related serious adverse events.

"We are thrilled to have our Phase III trial results fully disclosed and published in The Lancet, one of the world's most prestigious peer-reviewed medical journals. This represents another milestone and provides further evidence of the strong protection provided by our single-dose vaccine, which is now approved in at least 10 markets across multiple continents. CanSinoBIO remains committed to our mission of providing affordable, timely and mass immune protection to the global population, and will continue to collaborate with partners in the public and private sectors to improve vaccine access and have more people benefit from our technology breakthroughs," said Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO.

In addition to significantly shortening the vaccination cycle, Convidecia can be stably transported and stored between 2°C and 8°C, making it more accessible to regions with insufficient storage facilities and medical resources, reducing the burden placed on healthcare systems and medical workers, and contributing to building broad immune protection globally by leveraging the advantages of its single-dose regimen.

CanSinoBIO has also seen encouraging data in the trial of a booster dose of Convidecia for people inoculated with two doses of inactivated vaccines. Data showed that administering a booster dose of Convidecia could result in an approximately 78-fold increase in neutralizing antibody level 14 days post-vaccination. Additionally, administering a homologous booster dose of Convidecia six months after the prime immunization could result in a 7-fold increase in neutralizing antibody level.